Presentation to H.C. Wainwright Investment Conference
Filed with ASX · · 31 pages · English
13 – 15 September 2021 Authorised by the Board of Directors of Genetic Technologies Limited Notice: Forward looking statements The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they contain may require further ex
Genetic Technologies Limited on 6ix
In the deck
Earlier from Genetic Technologies
- Genetic Technologies FY21 Full Year Results
- Completion of EasyDNA Acquisition set for global expansion
- Genetic Technologies Investor Presentation and Webinar
- Genetic Technologies Acquires EasyDNA
- US Patent Office Grants Foundational Pharmacogenomic Patent
Later from Genetic Technologies
- GTG delivers material increase in cash receipts
- Momentum Building with Cash Receipts up 112% for Q2 FY22
- Quarterly Activities Report & Appendix 4C
- GeneType Multi-Test Approved for Commercial Release
- US Patent Office Grants Patent for COVID-19 Risk Test
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies